European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I
S. Krege(University of Lübeck), Ó. Leiva Galvis, J. R. Germa-Lluch(Institut Català d'Oncologia), Karim Fizazi(Université de Lille), Silke Gillessen(Institute of Oncology Research), Michael A.S. Jewett(Princess Margaret Cancer Centre), Maike de Wit(Florida Hospital Cancer Institute), Annette Dieing, Kai Uwe Koehrmann, Ronald de Wit(Erasmus MC Cancer Institute), I. Bodrogi(Aarhus University Hospital), Thomas Gauler, Robert Huddart(Institute of Cancer Research), Axel Heidenreich(Centrum für Integrierte Onkologie), Gedske Daugaard(Copenhagen University Hospital), Eva Cavallin‐Ståhl(Lund University), William G. Jones(The University of Texas Health Science Center at Houston), Sabine Kliesch(University Hospital Münster), Xavier García del Muro(Institut Català d'Oncologia), Pilar Laguna(Istanbul Medipol University), Rainer Souchon, Sophie D. Fosså(Oslo University Hospital), Johnathan Joffe, Michael Hartmann(Jena University Hospital), Peter Albers(Düsseldorf University Hospital), Martin Fenner(PEN American Center), C. Clemm(TUM Klinikum), Klaus‐Peter Dieckmann(Asklepios Klinik Altona), Gabriella Cohn‐Cedermark(Uppsala University Hospital), Maria De Santis(Medical University of Vienna), Carsten Bokemeyer(Universität Hamburg), Ferrán Algaba(Puigvert Foundation), Christian Kollmannsberger(BC Cancer Agency), Wolfgang Hoeltl, Lajos Géczi(National Institute of Oncology), L Kisbenedek, Johannes Claßen(St. Vincentius-Kliniken), Markus A. Kuczyk(Medizinische Hochschule Hannover), Stéphane Culine(Radboud University Nijmegen), Olbjørn Klepp, Hans Günter Derigs(Heidelberg University), A. Gerl(Ludwig-Maximilians-Universität München), Walter Albrecht(Rudolfinerhaus Hospital), Jörg T. Hartmann(University of Tübingen), Jean-Pierre Droz, Michael Bamberg(University of Tübingen), Aude Fléchon(Institut Català d'Ornitologia), P.H.M. de Mulder(Fondazione Vincenzo Pansadoro), A. Horwich(Institute of Cancer Research)
Cited by 617
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19
|Annals of Internal Medicine|2020|2.4k